Open Access
Med Buccale Chir Buccale
Volume 17, Number 2, Mai 2011
Page(s) 121 - 131
Section Mises au point / Literature reviews
Published online 18 April 2011
  1. Abu-Elmagd K, Jegasothy BV, Ackerman CD, Thomson AW, Rilo H, Nikolaidis N, Van Thiel D, Fung JJ, Todo S, Starzl TE. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. Transplant Proc 1991;23:3328-9. [PubMed] [Google Scholar]
  2. Abu-Elmagd K, Van Thiel DH, Jegasothy BV, Jacobs JC, Carroll P, Rodriquez-Rilo H, Ackerman CD, Fung JJ, Starzl TE. Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506). Ann Intern Med 1993;119:595-8. [CrossRef] [PubMed] [Google Scholar]
  3. Ackerman C, Abu-Elmagd K, Venkataramanan K, Fung G, Todo S, Starzl T, Jegasothy B. Recalcitrant psoriasis and pyoderma gangrenosum treated with FK 506 (abstract). J Invest Dermatol 1991;96:536 [Google Scholar]
  4. Ahmadi S, Powell FC. Pyoderma gangrenosum : uncommun presentations. Clin Dermatol 2005;23:612-20. [CrossRef] [PubMed] [Google Scholar]
  5. Akay N, Boyvat A, Heper AO, Soykan I, Arica IE, Bektas M, Ensari A, Cokca F. Behçet’s disease-like presentation of bullous pyoderma gangrenosum associated with Crohn’s disease. Clin Exp Dermatol 2006;31:384-6. [CrossRef] [PubMed] [Google Scholar]
  6. Basu MK, Asquith P. Oral manifestations of inflammatory bowel disease. Clin Gastroenterol 1980;9:307-21. [PubMed] [Google Scholar]
  7. Benett ML, Jackson JM, Jorizzo JL, Fleischer AB Jr, White WL, Callen JP. Pyoderma gangrenosum. A comparison of typical and atypical forms with emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000;79:37-41. [CrossRef] [PubMed] [Google Scholar]
  8. Bertram-Callens A, Marchet L, Vaillant L, Camenen I, Lorette G. Localisations buccales et oculaires de pyoderma gangrenosum au cours d’une maladie de Vaquez. Ann Dermatol Venerol 1991;118:611-4. [Google Scholar]
  9. Blitz NM, Rudikoff D. Pyoderma gangrenosum. Mt Sinai J Med 2001;68:287-97. [PubMed] [Google Scholar]
  10. Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA syndrome with recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009;161:1199-201. [CrossRef] [PubMed] [Google Scholar]
  11. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. Br Med J 2006;333:181-4. [CrossRef] [PubMed] [Google Scholar]
  12. Brown TS, Marshall GS, Callen JP. Cavitating pulmonary infiltrate in an adolescent with pyoderma gangrenosum : a rarely recognized extracutaneous manifestation of a neutrophilic dermatosis. J Am Acad Dermatol 2000;43:108-12. [CrossRef] [PubMed] [Google Scholar]
  13. Brunsting LA, Goeckerman WH, O’Leary IA. Pyoderma gangrenosum : clinical and experimental observations in five cases occurring in adults. Arch Dermatol 1930;22:655-80. [Google Scholar]
  14. Buckley C, Bayoumi AH, Sarkany I. Pyoderma gangrenosum with severe pharyngeal ulceration. J R Soc Med 1990;83:590-1. [PubMed] [Google Scholar]
  15. Bylaite M, Ruzicka T. Oral pyoderma gangrenosum : response to infliximab. 2009, [Google Scholar]
  16. Callen JP. Pyoderma gangrenosum. Lancet 1998;351:581-5. [CrossRef] [PubMed] [Google Scholar]
  17. Callen JP, Jackson JM. Pyoderma gangrenosum : an update. Rheum Dis Clin North Am 2007;33:787-802. [CrossRef] [PubMed] [Google Scholar]
  18. Callen JP, Taylor WB. Pyoderma gangrenosum – a literature review. Cutis 1978;21:61-4. [PubMed] [Google Scholar]
  19. Capella GL, Frigerio E, Fracchiolla C, Altomare G. The simultaneous treatment of inflammatory bowel disease and associated pyoderma gangrenosum with oral cyclosporin A. Scand J Gastroenterol 1999;34:220-1. [CrossRef] [PubMed] [Google Scholar]
  20. Carron PN, Yerly S, Ksontini R, Calandra T, Meylan P. Pyoderma gangrenosum : défi diagnostique et thérapeutique. Rev Med Suisse 2008;4:1938-43. [PubMed] [Google Scholar]
  21. Caughman W, Stern R, Haynes H. Neutrophilic dermatosis of myeloproliferative disorders. Atypical forms of pyoderma gangrenosum and Sweet’s syndrome associated with myeloproliferative disorders. J Am Acad Dermatol 1983;9:751-8. [CrossRef] [PubMed] [Google Scholar]
  22. Chams-Davatchi C, Shizapour M, Davatchi F, Shahram F, Chams H, Nadji A, Jamshidi AR. Extensive pyoderma gangrenosum like lesion in two cases of Behçet’s disease, responding only to cyclosporin. Adv Exp Med Bio 2003;528:337-8. [CrossRef] [Google Scholar]
  23. Charles CA, Bialy TL, Falabella AF, Eaglstein WH, Kerdel FA, Kirsner RS. Poor prognosis of arthritis-associated pyoderma gangrenosum. Arch Dermatol 2004;140:861-4. [CrossRef] [PubMed] [Google Scholar]
  24. Chow RK, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996;34:1047-60. [CrossRef] [PubMed] [Google Scholar]
  25. Conrad C, Truëb RM. Pyoderma gangrenosum. J Dtsch Dermatol Ges 2005;3:334-42. [CrossRef] [PubMed] [Google Scholar]
  26. Crowson AN, Mihm MC Jr, Magro C. Pyoderma gangrenosum : a review. J Cutan Pathol 2003;30:97-107. [CrossRef] [PubMed] [Google Scholar]
  27. Cummins DL, Anhalt GJ, Monahan T, Meyerle JH. Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Br J Dermatol 2007;157:1235-9. [CrossRef] [PubMed] [Google Scholar]
  28. Dai N, Richens J. Pyoderma gangrenosum in Papua New Guinea. P N G Med J 1990;33:247-51. [PubMed] [Google Scholar]
  29. Daniels NH, Callen JP. Mycophenolate mofetil is an effective treatment for peristomal pyoderma gangrenosum. Arch Dermatol 2004;140:1427-9. [CrossRef] [PubMed] [Google Scholar]
  30. Danzig PI. Pyoderma gangrenosum (letter). N Engl J Med 1975;292:47-8. [Google Scholar]
  31. Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastrolenterology 1990;98:464-9. [Google Scholar]
  32. Von den Driesch P. Pyoderma gangrenosum : a report of 44 cases with follow-up. Br J Dermatol 1997;137:1000-5. [CrossRef] [PubMed] [Google Scholar]
  33. Drinda S, Oelzner P, Canet CC, Kaatz M, Wolf G, Hein G. Fatal outcome of pyoderma gangrenosum with multiple organ involvement and partially responding to infliximab. CEJ Med 2006;1:306-12. [Google Scholar]
  34. Ehling A, Karrer S, Klebl F, Schäffler A, Müller-Ladner U. Therapeutic management of pyoderma gangrenosum. Arthritis Rheum 2004;50:3076-84. [CrossRef] [PubMed] [Google Scholar]
  35. Fahri D, Wallach D, Avril MF. Le pyoderma gangrenosum a 100 ans. De Louis Brocq aux biothérapies. Rev Prat 2008;58:457-61. [Google Scholar]
  36. tenFreyhaus KT, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum : another cutaneous side-effect of sunitinib? Br J Dermatol 2008;159:242-3. [CrossRef] [PubMed] [Google Scholar]
  37. Futami H, Kodaira M, Furuta T, Hanai H, Kaneko E. Pyoderma gangrenosum complicating ulcerative colitis : successful treatment with methylprednisolone pulse therapy and cyclosporine. J Gastroenterol 1998;33:408-11. [CrossRef] [PubMed] [Google Scholar]
  38. Gettler S, Rothe M, Grin C, Grant-Kels J. Optimal treatment of pyoderma gangrenosum. Am J Clin Dermatol 2003;4:597-608. [CrossRef] [PubMed] [Google Scholar]
  39. Goldfinger S. The inherited autoinflammatory syndrome : a decade of discovery. Trans Am Clin Climatol Assoc 2009;120:413-8. [PubMed] [Google Scholar]
  40. Goulden V, Bond L, Highet AS. Pyoderma gangrenosum associated with paroxysmal nocturnal haemoglobinuria. Clin Exp Dermatol 1994;19:271-3. [CrossRef] [PubMed] [Google Scholar]
  41. Gungor K, Gonen S, Kisakol G, Dikbas O, Kaya A. ANCA positive propylthiouracil induced pyoderma gangrenosum. J Endocrinol Invest 2006;29:575-6. [PubMed] [Google Scholar]
  42. Heffernan MP, Anadkat MJ, Smith DI. Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol 2007;143:306-8. [CrossRef] [PubMed] [Google Scholar]
  43. Hernández-Martín A, Arias-Palomo D, Hermida G, Gutiérrez-Ortega MC, Ramírez-Herrera M, Rodríguez-Vegas M, Velasco A. Oral pyoderma gangrenosum. Br J Dermatol 2003;149:663-4. [CrossRef] [PubMed] [Google Scholar]
  44. Hughes AP, Jackson JM, Callen JP. Clinical features and treatment peristomal pyoderma gangrenosum. J. Am Med Assoc 2000;284:1546-8. [CrossRef] [PubMed] [Google Scholar]
  45. Isomura I, Miyawaki S, Morita A. Pyoderma gangrenosum associated with nasal septal perforation, oropharyngeal ulcers and IgA paraproteinemia. J Dermatol 2005;32:193-8. [PubMed] [Google Scholar]
  46. Kennedy KS, Prendergast ML, Sooy CD. Pyoderma gangrenosum of the oral cavity, nose and larynx. Otolaryngol Head Neck Surg 1987;97:487-90. [PubMed] [Google Scholar]
  47. Kontochristopoulos G, Stavropoulos PG, Gregoriou S, Zakopoulou N. Treatment of pyoderma gangrenosum with low-dose colchicine. Dermatology 2004;209:233-6. [CrossRef] [PubMed] [Google Scholar]
  48. Krischer J, Modiano P, Saurat J-H. Pyoderma gangrenosum (pp 555-7). In Dermatologie et infections sexuellement transmissibles, 5e éd. Masson, Paris, 2009. [Google Scholar]
  49. Lachapelle JM, Marot L, Jablonska S. Superficial granulomatous pyoderma gangrenosum of the face, successfully treated by ciclosporine : a long-term follow-up. Dermatology 2001;202:155-7. [CrossRef] [PubMed] [Google Scholar]
  50. Lazarus GS, Goldsmith LA, Rocklin RE, Pinals RS, de Buisseret JP, David JR. Pyoderma gangrenosum, altered delayed hypersensitivity and polyarthritis. Arch Dermatol 1972;105:46-51. [CrossRef] [PubMed] [Google Scholar]
  51. Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEvoy MT. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum and acne : PAPA syndrome. Mayo Clin Proc 1997;72:611-5. [CrossRef] [PubMed] [Google Scholar]
  52. Margoles JS, Wenger J. Stomal ulceration associated with pyoderma gangrenosum and chronic ulcerative colitis. Report of two cases. Gastroenterology 1961;41:594-8. [Google Scholar]
  53. Marie I, Levesque H, Joly P, Reumont G, Courville P, Baudrimont M, Baubion D, Cailleux N, Courtois H. Neutrophilic myositis as an extracutaneous manifestation of neutrophilic dermatosis. J Am Acad Dermatol 2001;44:137-9. [CrossRef] [PubMed] [Google Scholar]
  54. McDougall AC, Horsfall WR, Hede JE, Chaplin AJ. Splenic infarction and tissue accumulation of crystals associated with the use of clofazimine (Lamprene; B663) in the treatment of pyoderma gangrenosum. Br J Dermatol 1980;102:227-30. [CrossRef] [PubMed] [Google Scholar]
  55. Michaelsson G, Molin L, Ohmann S, Gip L, Lindström B, Skogh M, Trolin I. Clofazimine : a new agent for treatment of pyoderma gangrenosum. Arch Dermatol 1976;112:344-9. [CrossRef] [PubMed] [Google Scholar]
  56. Munro CS, Cox NH. Pyoderma gangrenosum associated with Behçet’s syndrome - response to thalidomide. Clin Exp Dermatol 1988;13:408-10. [PubMed] [Google Scholar]
  57. Muster AJ, Bharati S, Herman JJ, Esterly NB, Gonzales-Crussi F, Holbrook KA. Fatal cardiovascular disease and cutis laxa following acute febrile neutrophilic dermatosis. J Pediatr 1983;102:243-8. [CrossRef] [PubMed] [Google Scholar]
  58. Nakamura T, Yagi H, Kurachi K, Suzuki S, Konno H. Intestinal Behçet’s disease with pyoderma gangrenosum : a case report. World J Gastroenterol 2006;12:979-81. [PubMed] [Google Scholar]
  59. Nurre LD, Rabalais GP, Callen JP. Neutrophilic dermatosis-associated sterile chronic multifocal osteomyelitis in pediatric patients : case report and review. Pediatr Dermatol 1999;16:214-6. [CrossRef] [PubMed] [Google Scholar]
  60. O’Loughlin S, Perry HO. A diffuse pustular eruption associated with ulcerative colitis. Arch Dermatol 1978;114:1061-4. [CrossRef] [PubMed] [Google Scholar]
  61. Park HJ, Han BG, Kim YC, Cinn YW. Recalcitrant oral pyoderma gangrenosum in a child responsive to cyclosporine. J Dermatol 2003;30:612-6. [PubMed] [Google Scholar]
  62. Perri AJ 3rd, Hsu S. A review of thalidomide’s history and current dermatological applications. Dermatol Online J 2003;9:5. [Google Scholar]
  63. Perry HO, Winkelmann RK. Bullous pyoderma gangrenosum and leukemia. Arch Dermatol 1972;106:901-5. [CrossRef] [PubMed] [Google Scholar]
  64. Philpott JA Jr, Goltz RW, Park RK. Pyoderma gangrenosum, rhumatoid arthritis, and diabetes mellitus. Arch Dermatol 1966;94:732-8. [CrossRef] [PubMed] [Google Scholar]
  65. Pomerantz RG, Husni ME, Mody E, Qureshi AA. Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol 2007;157:1274-5. [CrossRef] [PubMed] [Google Scholar]
  66. Powell FC, Collins S. Pyoderma gangrenosum. Clin Dermatol 2000;18:283-93. [CrossRef] [PubMed] [Google Scholar]
  67. Powell FC, Schroeter AL, Su WP, Perry HO. Pyoderma gangrenosum : a review of 86 patients. Q J Med 1985;55:173-86. [PubMed] [Google Scholar]
  68. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum : classification and management. J Am Acad Dermatol 1996;34:395-409. [CrossRef] [PubMed] [Google Scholar]
  69. Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum : an evidence-based review of literature based on more than 350 patients. J Am Acad Dermatol 2005;53:273-83. [CrossRef] [PubMed] [Google Scholar]
  70. Rozin AP, Balbir-Gurman A, Gilead L, Slodownik D. Combined therapy for pyoderma gangrenosum. Ann Rheum Dis 2004;63:888-9. [CrossRef] [PubMed] [Google Scholar]
  71. Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum : an update review. J Eur Acad Dermatol Venereol 2009;23:1008-17. [CrossRef] [PubMed] [Google Scholar]
  72. Sagara R, Kitami A, Nakada T, Iijima M. Adverse reactions to gefitinib (Iressa) : revealing sycosis- and pyoderma gangrenosum-like lesions. Int J Dermatol 2006;45:1002-3. [CrossRef] [PubMed] [Google Scholar]
  73. Sanders CJ, Hulsmans RF. Successful treatment of pyoderma gangrenosum with topical 5-aminosalicylic acid. Cutis 1993;51:262-4. [PubMed] [Google Scholar]
  74. Schöfer H, Baur S. Successful treatment of postoperative pyoderma gangrenosum with cyclosporin. J Eur Acad Dermatol Venereol 2002;16:148-51. [CrossRef] [PubMed] [Google Scholar]
  75. Scully C, Hodgson T, Lachmann H. Auto-inflammatory syndromes and oral health. Oral Dis 2008;14:690-9. [CrossRef] [PubMed] [Google Scholar]
  76. Setterfield JF, Shirlaw PJ, Challacombe SJ, Black MM. Pyoderma gangrenosum associated with severe oropharyngeal involvement and IgA paraproteinaemia. Br J Dermatol 2001;144:393-6. [CrossRef] [PubMed] [Google Scholar]
  77. Shaya S, Kindzelskii AL, Minor J, Moore EC, Todd 3rd RF, Petty HR. Aberrant integrin (CR4; alpha(x)beta2; CD11c/CD18) oscillations on neutrophils in a mild form of pyoderma gangrenosum. J Invest Dermatol 1998;111:154-8. [CrossRef] [PubMed] [Google Scholar]
  78. Smith JB, Shenefelt PD, Soto O, Valeriano J. Pyoderma gangrenosum in a patient with cryoglobulinemia and hepatitis C successfully treated with interferon alpha. J Am Acad Dermatol 1996;34:901-3. [CrossRef] [PubMed] [Google Scholar]
  79. Snyder RA. Pyoderma gangrenosum involving the head and neck. Arch Dermatol 1986;122:295-302. [CrossRef] [PubMed] [Google Scholar]
  80. Su WP, Schroeter AL, Perry HO, Powell FC. Histopathologic and immunopathologic study of pyoderma gangrenosum. J Cutan Pathol 1986;13:323-30. [CrossRef] [PubMed] [Google Scholar]
  81. Teitel AD. Treatment of pyoderma gangrenosum with methotrexate. Cutis 1996;57:326-8. [PubMed] [Google Scholar]
  82. Tsuboi H. Case of pyoderma gangrenosum showing oral and genital ulcers, misdiagnosed as Behçet’s disease at first medical examination. J Dermatol 2008;35:289-92. [CrossRef] [PubMed] [Google Scholar]
  83. Vadillo M, Jucgla A, Podzamczer D, Rufi G, Domingo A. Pyoderma gangrenosum with liver, spleen, and bone involvement in a patient with chronic myelomonocytic leukaemia. Br J Dermatol 1999;141:541-3. [CrossRef] [PubMed] [Google Scholar]
  84. Venencie PY, Saurat J-H. Pyoderma gangrenosum chez un enfant : traitement par la thalidomide. Ann Pediatr (Paris) 1982;29:67-9. [PubMed] [Google Scholar]
  85. Vidal D, Alomar A. Successful treatment of periostomal pyoderma gangrenosum using topical tacrolimus. Br J Dermatol 2004;150:387-8. [CrossRef] [PubMed] [Google Scholar]
  86. Vignon-Pennamen MD. The extracutaneous involvement in the neutrophilic dermatoses. Clin Dermatol 2000;18:339-47. [CrossRef] [PubMed] [Google Scholar]
  87. Wallach D. Les dermatoses neutrophiliques. Presse Med 1991;20:105-7. [PubMed] [Google Scholar]
  88. Wallach D. Les dermatoses neutrophiliques. Rev Med Interne 2005;26:41-53. [CrossRef] [PubMed] [Google Scholar]
  89. Weenig RH, Davis MD, Dahl PR, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med 2002;347:1412-8. [CrossRef] [PubMed] [Google Scholar]
  90. Wilson DM, John GR, Callen JP. Peripheral ulcerative keratitis – an extracutaneous neutrophilic disorder : report of a patient with rheumatoid arthritis, pustular vascularitis, pyoderma gangrenosum, and Sweet’s syndrome with an excellent response to cyclosporine therapy. J Am Acad Dermatol 1999;40:331-4. [CrossRef] [PubMed] [Google Scholar]
  91. Wilson-Jones E, Winkelmann RK. Superficial granulomatous pyoderma : a localized vegetative form of pyoderma gangrenosum. J Am Acad Dermatol 1988;18:511-21. [CrossRef] [PubMed] [Google Scholar]
  92. White LE, Villa MT, Petronic-Rosic V, Jiang J, Medenica MM. Pyoderma gangrenosum related to a new granulocyte colony-stimulating factor. Skinmed 2006;5:96-8. [CrossRef] [PubMed] [Google Scholar]
  93. Wollina U. Pyoderma gangrenosum – a review. Orphanet J Rare Dis 2007;2:19. [CrossRef] [PubMed] [Google Scholar]
  94. Yco MS, Warnock GR, Cruickshank JC, Burnett JR. Pyoderma gangrenosum involving the head and neck. Laryngoscope 1988;98:765-8. [PubMed] [Google Scholar]
  95. Yoshida C, Kojima H, Ishigaki T, Katsura Y, Kaneko S, Suzukawa K, Hasegawa Y, Kawachi Y, Otsuka F, Nagasawa T. Association of pyoderma gangrenosum and sterile osteomyelitis in a patient having myelodysplastic syndrome. Eur J Heamatol 2004;72:149-53. [CrossRef] [Google Scholar]
  96. Youdim A, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC, Lechago J, Paavola J, Loane J, Lee SK, Gaiennie J, Smith K, Do J, Abreu MT. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004;10:333-8. [CrossRef] [PubMed] [Google Scholar]
  97. Yusuf H, Ead RD. Pyoderma gangrenosum with involvement of the tongue. Br J Oral Maxillofac Surg 1985;23:247-50. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.